Akèy › Miasteni grav › North Carolina
Etid klinik pou Miasteni grav nan North Carolina
14 etid pou Miasteni grav ap chèche patisipan nan sit nan North Carolina.
Vil nan North Carolina
Tèks ofisyèl etid la (Anglè)
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Velocity Clinical Research, Inc., Raleigh
- Atrium Health Wake Forest Baptist, Winston-Salem
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Sep 25, 2026 · NCT07217587A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
- Cinical Study Site, Fayetteville
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 25, 2026 · NCT07647510ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- University of North Carolina at Chapel Hill-170 Manning Dr., Chapel Hill
- Duke Early Phase Clinical Research Unit - PPDS, Durham
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07294170ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- University of North Caroline at Chapel Hill-170 Manning Dr, Chapel Hill
- Duke Early Phase Clinical Research Unit - PPDS, Durham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07284420A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
- TG Therapeutics Investigational Trial Site, New Bern
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07673744Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- UNC Hospitals - PARENT, Chapel Hill
- Atrium Health Wake Forest Baptist, Winston-Salem
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06463587Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
- The University of North Carolina at Chapel Hill, Chapel Hill
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06414954Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1020, Chapel Hill
- Site Number - 1013, Durham
- Site Number - 1044, Raleigh
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT07039916A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Duke University School of Medicine, Durham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT04951622A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- University of North Carolina Hospitals - Neurology Clinic, Chapel Hill
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT06456580A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
- Research Site, Raleigh
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT07221838Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, Chapel Hill
- Clinical Trial Site, Charlotte
- Clinical Trial Site, Durham
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 18, 2026 · NCT04202341Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
- University of North Carolina at Chapel Hill, Chapel Hill
Ap rekriteFaz 2/3
Laj 2 a 18 · Tout sèks · Mizajou Feb 18, 2026 · NCT04833894The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
- Duke University, Durham
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Apr 11, 2025 · NCT05564936Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.